Tesamorelin vs AOD9604 compares a prescription GHRH analog with a synthetic fat-burning fragment: how each works, dosing, results, and safety.
Tesamorelin and AOD9604 are both peptides sold for fat loss, but they belong to completely different categories. Tesamorelin is an FDA-approved prescription GHRH analog that raises your body's own growth hormone, while AOD9604 is an unapproved fragment of human growth hormone sold mainly as a research chemical. The short answer on tesamorelin vs aod9604: tesamorelin has far stronger human trial data for visceral fat, and AOD9604 has thin evidence and no approved medical use.
What Is Tesamorelin?
Tesamorelin is a synthetic 44-amino-acid peptide that copies growth hormone-releasing hormone (GHRH). It binds GHRH receptors in the pituitary gland and prompts the body to release its own growth hormone, which then drives IGF-1 production in the liver.
The FDA approved tesamorelin, brand name Egrifta, for one narrow indication: reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy. The studied dose is 2 mg injected subcutaneously once daily.
Randomized trials in that population showed real reductions in visceral adipose tissue and improvements in some lipid measures. Tesamorelin is not approved for general weight loss or for cosmetic fat reduction in healthy adults.
What Is AOD9604?
AOD9604 is a modified piece of the human growth hormone molecule, corresponding to its 176-191 region. Researchers designed it to isolate the fat-metabolizing effects of GH while avoiding GH's effects on blood sugar and tissue growth.
It is not a GHRH analog and not a growth hormone secretagogue. AOD9604 does not meaningfully raise IGF-1 in published studies, which is one reason it is often marketed as a clean fat-loss peptide.
Human data is limited and mixed. The largest obesity trials of AOD9604 did not show a clear advantage over placebo for weight loss, and the compound was never approved by the FDA for any use.
Tesamorelin vs AOD9604: Head-to-Head Comparison
| Feature | Tesamorelin | AOD9604 |
|---|---|---|
| Peptide class | GHRH analog (44 amino acids) | Modified human GH fragment (176-191) |
| How it works | Stimulates pituitary GH release, which raises IGF-1 | Mimics a small GH fragment; minimal IGF-1 effect |
| FDA status | Approved for HIV-associated lipodystrophy | Not approved for any human use |
| Typical dose studied | 2 mg subcutaneous daily | 250-500 mcg daily reported in gray-market use |
| Human evidence | Multiple randomized trials showing visceral fat reduction | Limited; largest trials showed little advantage over placebo |
| Monitoring required | IGF-1, glucose, injection sites | None established; purity unverified |
| Legal status in the US | Prescription only | Not legal to sell as a drug or supplement |
The table captures the practical difference: one is a regulated medicine with a defined patient population, and the other is an experimental fragment whose efficacy remains unresolved.
How Their Mechanisms Differ
Tesamorelin acts upstream. It signals the pituitary to release growth hormone, producing a broad hormonal effect that touches fat, muscle, fluid balance, and connective tissue.
AOD9604 acts narrowly. It appears to mimic a small segment of GH that influences lipolysis and fat oxidation without triggering the full GH cascade.
That gap explains why their risk profiles look so different. Tesamorelin side effects come from real GH and IGF-1 elevation, while the main risk with AOD9604 comes from product quality rather than hormonal activity.
Side Effects, Risks, and Safety
Common tesamorelin side effects include injection-site reactions, joint and muscle pain, swelling in the hands and feet, and elevated IGF-1. It can affect blood sugar and is contraindicated in people with active cancer, pituitary tumors, or pregnancy.
Because tesamorelin raises IGF-1, it requires a prescription, periodic lab work, and clinical follow-up. That monitoring is a feature, not a burden.
The safety profile of AOD9604 is poorly characterized because high-quality human data is scarce, and no monitoring protocol exists for it.
The bigger practical risk is sourcing. Unapproved peptides sold online are frequently mislabeled, underdosed, or contaminated, and no regulatory body is checking any of it.
AOD9604 is also banned by the World Anti-Doping Agency, and it cannot legally be sold as a dietary supplement or prescription drug in the United States.
Which One Do People Actually Choose?
These two peptides are not interchangeable, and treating them as substitutes for each other is a mistake.
Search interest in aod 9604 vs tesamorelin has grown alongside the broader peptide boom, but the comparison favors tesamorelin on evidence quality alone.
Much of the confusion comes from stacking culture. AOD9604 is often bundled with a GHRH and a GHRP in lean-gains blends, and people then debate cjc-1295 ipamorelin vs tesamorelin as if they were competing versions of the same thing.
The same dynamic appears in any sermorelin vs tesamorelin or tesamorelin vs cjc-1295 no dac discussion, because all of these compounds raise endogenous growth hormone with different half-lives and very different amounts of clinical data.
For fat loss specifically, tesamorelin vs sermorelin vs ipamorelin comparisons usually miss the point: only tesamorelin carries an FDA-approved indication, and that indication is limited to one patient group.
Legal and Practical Considerations
Tesamorelin is a prescription drug in the United States and can only be obtained legally through a licensed pharmacy with a physician's prescription.
AOD9604 has no approved human use, and products sold under that name typically carry research-use-only or not-for-human-consumption labels.
Buying either peptide from an overseas or unverified vendor means accepting unknown purity, unknown dosing, and no recourse if something goes wrong.
Anyone considering these compounds for a health reason should talk with a licensed healthcare professional who can review labs, medical history, and goals first.
The Bottom Line
- Tesamorelin is FDA-approved for HIV-associated lipodystrophy and is not approved for general weight loss.
- AOD9604 is not FDA-approved for any human use and is sold primarily as a research chemical.
- Tesamorelin raises IGF-1 and requires lab monitoring; AOD9604 does not meaningfully raise IGF-1 in published data.
- AOD9604 has weaker human evidence than tesamorelin for reducing body fat.
- Neither peptide replaces diet, exercise, or medical care, and neither is risk-free.
Frequently Asked Questions
Is tesamorelin or AOD9604 better for fat loss?
Tesamorelin has stronger human evidence, with randomized trials showing reduced visceral abdominal fat in adults who have HIV-associated lipodystrophy. The largest obesity trials of AOD9604 did not show a clear advantage over placebo. Neither peptide is FDA-approved for general weight loss, so neither is a standard fat-loss treatment.
Is AOD9604 legal in the United States?
AOD9604 is not approved by the FDA for any human use, and it cannot legally be sold as a dietary supplement or prescription drug. Products labeled AOD9604 are typically sold as research chemicals with not-for-human-consumption warnings. It is also banned by the World Anti-Doping Agency.
Can you stack tesamorelin and AOD9604 together?
There is no published clinical research on combining tesamorelin and AOD9604, and they act through different pathways. Stacking them is a theoretical idea rather than a tested protocol. Combining an unapproved research chemical with a prescription drug adds risk without adding evidence, so a physician should be involved in any decision.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.